narasimhan: we are looking at innovative models.are most interested in payments over time, or rebates for performance. the big shift we need the world to make is going from where we are used to getting pills over 40 years that have a small incremental effect, to a single infusion that has a transformational effect. we made that shift, the payment models have to shift. we are innovating and talking to a broad range of partners. manus: my print colleagues will not let me out of the building if i do not ask, you up the guidance with operating income. your target mid-30's by 2022. with this guidance, can i push you for a reflection? would you upgrade that? dr. narasimhan: we are sticking to mid 30's and 2022. we did get to 33.3 in the first quarter. one of the drivers is great live performance, all of the sales drivers doing well. also new launches starting to kick in. the other i am happy about is our productivity initiative taking hold. we are working on a massive transformation, one of the most the industry. also a complete transform